Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 2/20 | 0.44 |
| ▸ | CFTR | P13569 | 6/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.39 |
| ▸ | HTR7 | P34969 | 3/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 3/20 | 0.37 |
| ▸ | JAK3 | P52333 | 3/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14935590 | 0.76 | LMNA (0.40) | CFTRPIK3CDPIK3R1DYRK1BGRM4 | |
| SCHEMBL14947696 | 0.76 | PIK3CD (0.44) | PIK3CDPIK3R1 | |
| SCHEMBL30047569 | 0.74 | HTR7 (0.58) | PLK1PIK3CDPIK3R1HTR7JAK2 | |
| SCHEMBL18878391 | 0.73 | GRM4 (0.45) | CFTRDYRK1BGRM4 | |
| SCHEMBL17040353 | 0.72 | RAB9A (0.44) | CFTRDYRK1BMEN1KMT2AGRM4 | |
| SCHEMBL14935560 | 0.72 | CFTR (0.45) | CFTRDYRK1BGRM4 | |
| SCHEMBL20162913 | 0.71 | CFTR (0.50) | CFTR | |
| SCHEMBL14947693 | 0.70 | GRM4 (0.43) | CFTRDYRK1BGRM4 | |
| SCHEMBL14947692 | 0.70 | GRM4 (0.43) | CFTRDYRK1BGRM4 | |
| SCHEMBL20282465 | 0.68 | CFTR (0.44) | CFTRDYRK1BGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123281-A1 | Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules | BETA CAT PHARMACEUTICALS, LLC (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123281-A1 | Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules | BETA CAT PHARMACEUTICALS, LLC (US) | 2013-05-16 | — | — | US | disclosed |
| WO-2013071232-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF TBL-1 BINDING TO DISEASE-ASSOCIATED MOLECULES | BETA CAT PHARMACEUTICALS, LLC (US) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123281-A1 | Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules | TBL2, TBL3, TBL1XR1 | PLK1 1845/4885CFTR 1401/4885PIK3CD 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.